ProKidney Total Liab from 2010 to 2024

PROK Stock  USD 1.85  0.03  1.60%   
ProKidney Corp Total Liabilities yearly trend continues to be quite stable with very little volatility. Total Liabilities may rise above about 30.7 M this year. Total Liabilities is the total amount of all liabilities that ProKidney Corp has, including both short-term and long-term liabilities. View All Fundamentals
 
Total Liabilities  
First Reported
2010-12-31
Previous Quarter
29.2 M
Current Value
30.7 M
Quarterly Volatility
9.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check ProKidney Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ProKidney Corp's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.4 M, Interest Expense of 11.4 K or Selling General Administrative of 29.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. ProKidney financial statements analysis is a perfect complement when working with ProKidney Corp Valuation or Volatility modules.
  
Check out the analysis of ProKidney Corp Correlation against competitors.
For more information on how to buy ProKidney Stock please use our How to buy in ProKidney Stock guide.

Latest ProKidney Corp's Total Liab Growth Pattern

Below is the plot of the Total Liab of ProKidney Corp over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. ProKidney Corp's Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ProKidney Corp's overall financial position and show how it may be relating to other accounts over time.
Total Liab10 Years Trend
Slightly volatile
   Total Liab   
       Timeline  

ProKidney Total Liab Regression Statistics

Arithmetic Mean8,693,787
Geometric Mean6,062,393
Coefficient Of Variation106.31
Mean Deviation6,874,087
Median3,724,000
Standard Deviation9,242,220
Sample Variance85.4T
Range27M
R-Value0.75
Mean Square Error39.7T
R-Squared0.57
Significance0
Slope1,558,038
Total Sum of Squares1195.9T

ProKidney Total Liab History

202430.7 M
202329.2 M
202213.1 M
202113.4 M
20206.8 M

About ProKidney Corp Financial Statements

ProKidney Corp investors utilize fundamental indicators, such as Total Liab, to predict how ProKidney Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Total Liabilities29.2 M30.7 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether ProKidney Corp is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if ProKidney Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Prokidney Corp Stock. Highlighted below are key reports to facilitate an investment decision about Prokidney Corp Stock:
Check out the analysis of ProKidney Corp Correlation against competitors.
For more information on how to buy ProKidney Stock please use our How to buy in ProKidney Stock guide.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProKidney Corp. If investors know ProKidney will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProKidney Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.54)
Return On Assets
(0.20)
Return On Equity
(0.31)
The market value of ProKidney Corp is measured differently than its book value, which is the value of ProKidney that is recorded on the company's balance sheet. Investors also form their own opinion of ProKidney Corp's value that differs from its market value or its book value, called intrinsic value, which is ProKidney Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProKidney Corp's market value can be influenced by many factors that don't directly affect ProKidney Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProKidney Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if ProKidney Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProKidney Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.